Immunogenic Cell Death in Hematological Malignancy Therapy.

Zhaoyun Liu, Xintong Xu, Kaining Liu, Jingtian Zhang, Dan Ding, Rong Fu

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2023 May

filter terms:

Although the curative effect of hematological malignancies has been improved in recent years, relapse or drug resistance of hematological malignancies will eventually recur. Furthermore, the microenvironment disorder is an important mechanism in the pathogenesis of hematological malignancies. Immunogenic cell death (ICD) is a unique mechanism of regulated cell death (RCD) that triggers an intact antigen-specific adaptive immune response by firing a set of danger signals or damage-associated molecular patterns (DAMPs), which is an immunotherapeutic modality with the potential for the treatment of hematological malignancies. This review summarizes the existing knowledge about the induction of ICD in hematological malignancies and the current research on combining ICD inducers with other treatment strategies for hematological malignancies. © 2023 The Authors. Advanced Science published by Wiley-VCH GmbH.

Citation

Zhaoyun Liu, Xintong Xu, Kaining Liu, Jingtian Zhang, Dan Ding, Rong Fu. Immunogenic Cell Death in Hematological Malignancy Therapy. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2023 May;10(13):e2207475